Sage Journals: Discover world-class research

Abstract

Objective:

To analyze the effectiveness of an electrotherapy intervention with galvanic current on symptoms associated with Raynaud’s phenomenon.

Design:

Single-blind randomized controlled trial, parallel design (1:1 ratio) and intention-to-treat analysis.

Setting:

Virgen de las Nieves Hospital, Granada, Spain.

Subjects:

Thirty-four participants with Raynaud’s phenomenon, with a mean (SD) age of 43.43 (17.62) years.

Interventions:

The patients were randomly assigned to a control group with conservative treatment (anti-inflammatory, vasodilatory and analgesic drugs) or an intervention group that received conservative treatment and vasodilatory electrical stimulation during seven weeks, three times/week for a total of 20 sessions.

Main measures:

The primary outcome was the number of attacks. Secondary outcomes were pain, peripheral blow flow, oxygen saturation, upper limb disability, central sensitization, pain catastrophizing and temperature recovery. All outcomes were assessed at baseline, posttreatment and at two months of follow-up.

Results:

The galvanic current electrotherapy group showed significantly greater improvements in the number of attacks (mean difference = 26.3, 95% confidence interval (CI) = 14.4 to 38.3), pre-cold stress pain (95% CI = 0.6 to 2.4), radial artery blood flow (95% CI = −7.8 ⩾ x ⩽ 1.3), ulnar artery blood flow (95% CI = −8.63 to 0.60), oxygen saturation (95% CI = −1.7 ⩾ x ⩽ −0.29), upper limb disability (95% CI = 1.1 to 22.3), central sensitization (95% CI = 6.7 to 18.2) and temperature recovery (95% CI = −5.7 ⩾ x ⩽ −0.32) than the conservative treatment group.

Conclusion:

This study suggests that a complementary treatment with galvanic current in combination to conservative approach is superior to conservative applied as isolate, in reducing the clinical manifestations and disability in Raynaud’s phenomenon.

Keywords

Raynaud disease electric stimulation therapy randomized controlled trial

Get full access to this article

View all access options for this article.

References

Stringer

Femia

. Raynaud’s phenomenon: current concepts. Clin Dermatol 2018; 36(4): 498–507.

Belch

Carlizza

Carpentier

, et al. ESVM guidelines—the diagnosis and management of Raynaud’s phenomenon. Vasa 2017; 46(6): 413–423.

Herrick

AL.

Therapeutic implications from the pathogenesis of Raynaud’s phenomenon. Expert Rev Clin Immunol 2017; 13(7): 723–735.

Wigley

Flavahan

. Raynaud’s phenomenon. N Engl J Med 2016; 375(6): 556–565.

Linnemann

Erbe

. Raynaud’s phenomenon and digital ischaemia—pharmacologic approach and alternative treatment options. Vasa 2016; 45(3): 201–212.

Bérezné

Seror

Morell-Dubois

, et al. Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers. Arthritis Care Res 2011; 63(2): 277–285.

Murray

Herrick

Gorodkin

, et al. Possible therapeutic use of vasodilator iontophoresis. Microvasc Res 2005; 69(1–2): 89–94.

Anderson

Moore

Lunt

, et al. Digital iontophoresis of vasoactive substances as measured by laser Doppler imaging—a non-invasive technique by which to measure microvascular dysfunction in Raynaud’s phenomenon. Rheumatology 2004; 43(8): 986–991.

Ojingwa

Isseroff

. Electrical stimulation of wound healing. J Invest Dermatol 2003; 121(1): 1–12.

10.

Murray

Moore

King

, et al. Vasodilator iontophoresis a possible new therapy for digital ischaemia in systemic sclerosis? Rheumatology 2008; 47(1): 76–79.

11.

Little

Murray

Dinsdale

, et al. Whole finger iontophoresis of sodium nitroprusside to increase blood flow in patients with systemic sclerosis: influence of concentration. Int J Pharm 2015; 490(1–2): 446–449.

12.

LeRoy

Medsger

Jr . Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 1992; 10(5): 485–488.

13.

Chlebicka

Matusiak

Maj

, et al. Freezing fingers syndrome, primary and secondary Raynaud’s phenomenon: characteristic features with hand thermography. Acta Derm Venereol 2013; 93(4): 428–432.

14.

Bijur

Silver

Gallagher

. Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med 2001; 8(12): 1153–1157.

15.

Dworkin

Turk

Wyrwich

, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9(2): 105–121.

16.

Toprak

Selvi

Ates

, et al. Dynamic Doppler evaluation of the hand arteries of the patients with Raynaud’s disease. Clin Rheumatol 2009; 28(6): 679–683.

17.

Plana

Zamora

Suresh

, et al. Pulse oximetry screening for critical congenital heart defects. Cochrane Database Syst Rev 2018; 3: CD011912.

18.

Hervas

Navarro Collado

Peiro

, et al. Spanish version of the DASH questionnaire. Cross-cultural adaptation, reliability, validity and responsiveness. Med Clin 2006; 127(12): 441–447.

19.

Gummesson

Ward

Atroshi

. The shortened disabilities of the arm, shoulder and hand questionnaire (QuickDASH): validity and reliability based on responses within the full-length DASH. BMC Musculoskelet Disord 2006; 7: 44–51.

20.

Sorensen

Howard

Tan

, et al. Minimal clinically important differences of three patient-rated outcomes instruments. J Hand Surg Am 2013; 38(4): 641–649.

21.

Neblett

Cohen

Choi

, et al. The Central Sensitization Inventory (CSI): establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. J Pain 2013; 14(5): 438–445.

22.

Sullivan

MJL

Bishop

Pivik

. The Pain Catastro-phizing Scale: development and validation. Psychol Assess 1995; 7: 524–532.

23.

Grossi

Mariotti

Di Donato

, et al. Functional infrared imaging of paroxysmal ischemic events in patients with Raynaud’s phenomenon. Int J Immunopathol Pharmacol 2010; 23(2): 627–632.

24.

Ismail

Orlando

Corradini

, et al. Differential diagnosis of Raynaud’s phenomenon based on modeling of finger thermoregulation. Physiol Meas 2014; 35(4): 703–716.

25.

Aguilar-Ferrándiz

Moreno-Lorenzo

Matarán-Peñarrocha

, et al. Effects of tap water iontophoresis and psychological techniques on psychosocial aspects of primary palmar hyperhidrosis. Eur J Dermatol 2011; 21(2): 256–258.

26.

Denton

Hachulla Riemekasten

ÉG

Schwarting

, et al. Efficacy and safety of selexipag in adults with Raynaud’s phenomenon secondary to systemic sclerosis: a Randomized, Placebo-Controlled, Phase II study. Arthritis Rheumatol 2017; 69(12): 2370–2379.

27.

Gollins

Carpenter

Steen

, et al. A retrospective analysis of the use of tap water iontophoresis for focal hyperhidrosis at a district general hospital: the patients’ perspective. J Dermatolog Treat 2019; 30(7): 724–726.

28.

Saki

Hosseinpoor

Heiran

, et al. Comparing the efficacy of triamcinolone acetonide iontophoresis versus topical calcipotriol/betamethasone dipropionate in treating nail psoriasis: a bilateral controlled clinical trial. Dermatol Res Pract 2018; 2018: 2637691.

29.

Roustit

Gaillard-Bigot

Blaise

, et al. Cutaneous iontophoresis of treprostinil in systemic sclerosis: a proof-of-concept study. Clin Pharmacol Ther 2014; 95(4): 439–445.

30.

Kolkhorst

Di Pasquale

Buono

. Effect of tap-water iontophoresis on sweat gland recruitment, skin temperature and skin blood flow. J Dermatol Sci 2002; 28(2): 97–101.

31.

Rirash

Tingey

Harding

, et al. Calcium channel blockers for primary and secondary Raynaud’s phenomenon. Cochrane Database Syst Rev 2017; 12: CD000467.

32.

Ingegnoli

Schioppo

Allanore

, et al. Practical suggestions on intravenous iloprost in Raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus. Semin Arthritis Rheum 2019; 48(4): 686–693.

33.

Chung

Shapiro

Fiorentino

, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon. Arthritis Rheum 2009; 60(3): 870–877.

34.

Bello

Cooney

Melamed

, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud’s phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol 2017; 69(8): 1661–1669.

35.

Shenoy

Kumar

Jha

, et al. Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology 2010; 49(12): 2420–2428.

36.

Nijs

Malfliet

Ickmans

, et al. Treatment of central sensitization in patients with “unexplained” chronic pain: an update. Expert Opin Pharmacother 2014; 15(12): 1671–1683.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.13 MB

The complementary effects of galvanic current electrical stimulation associated with conservative treatment to increase vasodilation in patients with Raynaud’s phenomenon: a randomized trial

Abstract

Objective:

Design:

Setting:

Subjects:

Interventions:

Main measures:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material